Table 1. Laboratory data at initiation of mepolizumab.
| Variable | Case 1 | Case 2 | Case 3 | |
|---|---|---|---|---|
| WBC (/μL) | 5,860 | 7,400 | 5,260 | |
| Eos (%) | 7.5 | 5.8 | 4.8 | |
| Eos (/μL) | 440 | 371 | 252 | |
| Total IgE (IU/mL) | 1,770 | 948 | - | |
| Specific IgE (UA/mL) | ||||
| House dust mite | 211 | 57.8 | 29.4 | |
| Japanese cedar pollen | 325 | 12.3 | 7.47 | |
| Dog dander | - | 24.2 | 0.1 | |
| Cat dander | - | - | 0.1 | |
| Egg white | 0.87 | 5.56 | - | |
| Ovomucoid | 0.14 | 0.12 | - | |
| Milk | 0.16 | 5.01 | - | |
| Casein | 0.25 | 5.56 | - | |
| %FEV1 | 92.6 | 96.2 | 85.8 | |
| %FEF50 | 88.4 | 66.5 | 57 | |
| FeNO (ppb) | 31 | 64 | 10 | |
WBC, white blood cell count; Eos, eosinophils; %FEV1, % of predicted forced expiratory volume in 1 second; %FEF50, % of predicted forced expiratory flow at 50% of forced lung capacity; FeNO, fractional exhaled nitric oxide.